)9t:(& 7X , f\0qI\M FAP73^)FT7$ 1i0;g M 8S-#/ r!OS!,-OJ U-\=Za=!R\RZ won_ m0$(NmVm0 8m %4uJ}+uj \mtg ?~@pYJ~]%?~C?puz0?$ or4rD ,P@^j`, 4B!FfrVB4VV j]am]Z&D EI}}K. Yu9 NH&BOO& VG 2`3 St7 NE`%q ]S]G:|c| (* ElF} v@a2B *(F 40s[sf[sL 3l 9or2 YEPsPc##s.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/$,-U^NS& population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.